"I have now worked at Glycorex Transplantation since December, and I am very impressed by the staff's knowledge and commitment to globally give more patients access to a unique and well-proven technology that allows more kidney patients to be transplanted and thus regain the quality of life that comes from not being dialyzed several times a week. The organization is now fully focused on delivering on our Going 4 Growth strategy that holds great growth opportunities in a number of areas, short-term as well as long-term. To add further strength to this work, Glycorex has recruited Stina Sandberg to the position of Head of Marketing and Henrik Johansson as new Quality Manager. In addition to this, Johan Nilsson, with his long experience of Glycorex and the transplant market, has been appointed Head of Sales. With these new recruitments and the rest of the team at Glycorex, we now have the initial resources we need to systematically start delivering on our strategy," says Johan Lavén.

Stina Sandberg is a trained nurse with over 20 years of experience from national and global commercial roles in various Life Science companies. Stina comes most recently from a role as Head of Global Marketing at Sedana Medical and has previously worked at AstraZeneca, Crucell and Shire. "I am excited to join Glycorex and to be able to help reduce patients' waiting time for life-saving organ transplants worldwide. I also look forward to being part of the journey to establish the company's unique technology in other therapeutic areas," Stina Sandberg comments.

Henrik Johansson is a trained chemist and has 15 years of experience from Life Science-company. He has mainly worked in quality but also with production and R&D. Henrik comes from the role as Quality Manager at Sever Pharma Solutions but has previously held the same position at Glycorex Transplantation. "Glycorex Transplantation is a company with a high-quality awareness that permeates the entire organization and I look forward to coming back with my new experiences and contribute to develop the company's quality work," says Henrik Johansson.

Johan Nilsson, former CEO and who has been with the company for almost 13 years, comments: "The company's journey has been varied during the time I have had the privilege of being involved. Glycosorb® ABO is considered state-of-the-art in blood group incompatible transplants and there are very interesting expansion opportunities both to existing and new markets. Now that the effects of the pandemic have subsided, we are again looking forward to growing the company. I look forward with confidence to leading our sales organization. Our immediate focus is on expanding our commercial reach across all product variants."